Skip to main content

Marsico Lung Institute faculty, postdoc, student, and collaborator publications for January 2024 included papers appearing in The Lancet Respiratory Medicine, Advanced Science, and Proceedings of the National Academy of Sciences USA. Check out the full list below:

  1. McCullough MJ, Tune MK, Cabrera JC, Torres-Castillo J, He M, Feng Y, Doerschuk CM, Dang H, Beltran AS, Hagan RS, Mock JR. Characterization of the MT-2 Treg-like cell line in the presence and absence of forkhead box P3 (FOXP3). Immunol Cell Biol. 2024 Jan 30. doi: 10.1111/imcb.12725. Epub ahead of print. PMID: 38288547.
  2. Opron K, Begley LA, Erb-Downward JR, Li G, Alexis NE, Barjaktarevic I, Barr RG, Bleecker ER, Boucher R, Bowler RP, Christenson SA, Comellas AP, Criner G, Cooper CB, Couper D, Galban CJ, Han MK, Hastie A, Hatt C, Hoffman EA, Kaner RJ, Kesimer M, Krishnan JA, LaFon DC, Martinez FJ, Ortega VE, Peters SP, Paine Iii R, Putcha N, Woodruff PG, Huffnagle GB, Kozik AJ, Curtis JL, Huang YJ; SPIROMICS Investigators. Loss of Airway Phylogenetic Diversity Is Associated with Clinical and Pathobiological Markers of Disease Development in COPD. Am J Respir Crit Care Med. 2024 Jan 23. doi: 10.1164/rccm.202303-0489OC. Epub ahead of print. PMID: 38261629.
  3. He Z, Chu C, Dickson R, Okuda K, Cai L. A gel-coated air-liquid-interface culture system with tunable substrate stiffness matching healthy and diseased lung tissues. Am J Physiol Lung Cell Mol Physiol. 2024 Jan 22. doi: 10.1152/ajplung.00153.2023. Epub ahead of print. PMID: 38252871.
  4. Smolak P, Nguyen M, Diamond C, Wescott H, Doedens JR, Schooley K, Snouwaert JN, Bock MG, Harrison D, Watt AP, Koller BH, Gabel CA. Target cell activation of a structurally novel NLRP3 inhibitor NT-0796 enhances potency. J Pharmacol Exp Ther. 2024 Jan 22:JPET-AR-2023-001941. doi: 10.1124/jpet.123.001941. Epub ahead of print. PMID: 38253384.
  5. Benaim E, Jaspers I. Surgical smoke and its components, effects, and mitigation: a contemporary review. Toxicol Sci. 2024 Jan 18:kfae005. doi: 10.1093/toxsci/kfae005. Epub ahead of print. PMID: 38243717.
  6. Saeed MS, Denoncourt CM, Chao IA, Schortmann S, Nassikas NJ, Synn AJ, Koutrakis P, Coull BA, Kang CM, Wolfson JM, Ferguson ST, Rebuli ME, Jaspers I, Liu JP, Greco KF, Phipatanakul W, Rice MB. Protocol for the air purification for eosinophilic COPD study (APECS): a randomised controlled trial of home air filtration by HEPA. BMJ Open. 2024 Jan 18;14(1):e074655. doi: 10.1136/bmjopen-2023-074655. PMID: 38238060; PMCID: PMC10806745.
  7. Pleasants RA, Henderson AG, Bayer V, Shaikh A, Drummond MB. Effect on Physical Position of Peak Inspiratory Flow in Stable COPD: An Observational Study. Chronic Obstr Pulm Dis. 2024 Jan 17. doi: 10.15326/jcopdf.2023.0460. Epub ahead of print. PMID: 38236166.
  8. Parsons JB, Sidders AE, Velez AZ, Hanson BM, Angeles-Solano M, Ruffin F, Rowe SE, Arias CA, Fowler VG Jr, Thaden JT, Conlon BP. In-patient evolution of a high-persister Escherichia coli strain with reduced in vivo antibiotic susceptibility. Proc Natl Acad Sci U S A. 2024 Jan 16;121(3):e2314514121. doi: 10.1073/pnas.2314514121. PMID: 38190524; PMCID: PMC10801923.
  9. Burbank AJ, Laux J, Brown J, Sims M, Ivins S, Hernandez ML. Home spirometry monitoring to identify loss of asthma control in adolescents. Pediatr Pulmonol. 2024 Jan 15. doi: 10.1002/ppul.26856. Epub ahead of print. PMID: 38224240.
  10. Gentzsch M, Baker B, Cholon DM, Kam CW, McKinzie CJ, Despotes KA, Boyles SE, Quinney NL, Esther CR Jr, Ribeiro CMP. Cystic fibrosis airway inflammation enables elexacaftor/tezacaftor/ivacaftor-mediated rescue of N1303K CFTR mutation. ERJ Open Res. 2024 Jan 15;10(1):00746-2023. doi: 10.1183/23120541.00746-2023. PMID: 38226069; PMCID: PMC10789252.
  11. McSweeney MD, Alnajjar S, Schaefer AM, Richardson Z, Wolf W, Stewart I, Sriboonyapirat P, McCallen J, Farmer E, Nzati B, Lord S, Farrer B, Moench TR, Kumar PA, Arora H, Pickles RJ, Hickey AJ, Ackermann M, Lai SK. Inhaled “Muco-Trapping” Monoclonal Antibody Effectively Treats Established Respiratory Syncytial Virus (RSV) Infections. Adv Sci (Weinh). 2024 Jan 15:e2306729. doi: 10.1002/advs.202306729. Epub ahead of print. PMID: 38225749.
  12. Kos R, Goutaki M, Kobbernagel HE, Rubbo B, Shoemark A, Aliberti S, Altenburg J, Anagnostopoulou P, Athanazio RA, Beydon N, Dell SD, Emiralioglu N, Ferkol TW, Loebinger MR, Lorent N, Maître B, Marthin J, Morgan LC, Nielsen KG, Ringshausen FC, Shteinberg M, Tiddens HAWM, Maitland-Van der Zee AH, Chalmers JD, Lucas JSA, Haarman EG. A BEAT-PCD consensus statement: a core outcome set for pulmonary disease interventions in primary ciliary dyskinesia. ERJ Open Res. 2024 Jan 8;10(1):00115-2023. doi: 10.1183/23120541.00115-2023. PMID: 38196895; PMCID: PMC10772902.
  13. Patel N, Ansar M, Pham A, Thomsen K, McKinzie CJ, Polineni D, Esther CR Jr, Brown RF. Gilbert’s syndrome leads to elevated bilirubin after initiation of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis. Pediatr Pulmonol. 2024 Jan 5. doi: 10.1002/ppul.26831. Epub ahead of print. PMID: 38179880.
  14. Ringshausen FC, Shapiro AJ, Nielsen KG, Mazurek H, Pifferi M, Donn KH, van der Eerden MM, Loebinger MR, Zariwala MA, Leigh MW, Knowles MR, Ferkol TW; CLEAN-PCD investigators and study team. Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): A multinational, phase 2, randomised, double-blind, placebo-controlled crossover trial. Lancet Respir Med. 2024 Jan;12(1):21-33. doi: 10.1016/S2213-2600(23)00226-6. PMID: 37660715.
  15. Sears PR, Ostrowski LE. Mucociliary Transport Device Construction and Application to Study Mucociliary Clearance. Methods Mol Biol. 2024;2725:263-276. doi: 10.1007/978-1-0716-3507-0_17. PMID: 37856031.